Ute Scholl

Prof. Dr. med.
Principal Investigator

Berlin Institute of Health at Charité
Hessische Str. 3/4
10015 Berlin

Current Position

BIH Johanna Quandt Professor (W2, tenure track)

Academic Education

2001 - 2007 Studies of Human Medicine (M.D.), RWTH Aachen University

Advanced Qualifications

2008 Doctoral degree in medicine (Dr. med.), RWTH Aachen University

Postgraduate Positions

2017 - present BIH Johanna Quandt Professor for Hypertension and Molecular Biology of Endocrine Tumors, Charité – Universitätsmedizin Berlin
2017 - 2018 Research Group Leader, Division of Nephrology, Heinrich Heine University Düsseldorf
2016 - 2017 Resident in Nephrology / Internal Medicine, University Hospital Düsseldorf
2014 - 2017 Assistant Professor, Experimental Nephrology and Hypertension, Heinrich Heine University Düsseldorf
2013 - 2014 Junior Research Group Leader, Division of Nephrology, Heinrich Heine University Düsseldorf
2011 - 2013 Visiting Scholar and Postdoctoral Associate, Department of Genetics, Yale University School of Medicine, New Haven, USA
2011 Resident in Nephrology / Internal Medicine, Medical Center - University of Freiburg
2008 - 2011 Postdoctoral Associate and Fellow, Department of Genetics, Yale University School of Medicine, New Haven, USA
2007 - 2008 Research Associate, Department of Neurophysiology, Hannover Medical School

Link to all publications of Ute Scholl: PubMed

Publications on CRC 1453 funding

Dannenberg F, von Moers A, Bittigau P, …, Broekema MF, Schuelke M, Kaindl AM, Scholl U, Ortner NJ. A Novel De Novo Gain-of-Function CACNA1D Variant in Neurodevelopmental Disease With Congenital Tremor, Seizures, and Hypotonia. Neurol Genet (2024). Stölting G, Dinh HA, Volkert M, Hellmig N, Schewe J, …, Rivalan M, Nottoli T, Scholl UI. Isradipine therapy in Cacna1dIle772Met/+ mice ameliorates primary aldosteronism and neurologic abnormalities. JCI Insight (2023). Dinh HA, Stölting G, Scholl UI. CaV3.2 (CACNA1H) in Primary Aldosteronism. Handb Exp Pharmacol (2023). Scholl UI. Genetics of Primary Aldosteronism. Hypertension (2022). Etges A, Hellmig N, Walenda G, Haddad BG, Machtens JP, Morosan T, Rump LC, Scholl UI. A Novel Homozygous KLHL3 Mutation as a Cause of Autosomal Recessive Pseudohypoaldosteronism Type II Diagnosed Late in Life. Nephron (2022).